Verici Dx: Edison Open House Healthcare 2022

Verici Dx: Edison Open House Healthcare 2022

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes.

• Tell us about your patient-based focus in the area of kidney transplant.
• Which research underpins your platform?
• How does this open up treatment options?
• What does the US designation of laboratory developed tests (LDT) mean for Clarava and Tuteva, and how does the commercialisation strategy differ in other markets?
• Might the technology work for other types of organ transplant?
• What are your licensing and intellectual property strategies?
• Which milestones should investors focus on in the coming year?


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.